Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Key Points

• Lexeo Therapeutics CFO Louis Edward Tamayo sold 4,117 shares at an average price of $4.91, generating $20,214.47. The sale covered tax-withholding obligations, reducing his ownership by 4.24% to 92,907 shares.
• Lexeo shares rose to $5.37 during mid-day trading, while the company reported a quarterly loss of $0.30 per share, slightly missing analysts’ $0.29-loss estimate.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an $18.75 price target, although recent ratings and target changes have been mixed. Institutional investors own approximately 60.67% of the company.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CFO Louis Edward Tamayo sold 4,117 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $4.91, for a total transaction of $20,214.47. Following the completion of the transaction, the chief financial officer owned 92,907 shares in the company, valued at approximately $456,173.37. This trade represents a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Louis Edward Tamayo also recently made the following trade(s):

• On Wednesday, July 1st, Louis Edward Tamayo sold 4,641 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $4.49, for a total transaction of $20,838.09.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ LXEO traded up $0.44 during mid-day trading on Wednesday, hitting $5.37. 941,872 shares of the stock were exchanged, compared to its average volume of 952,662. Lexeo Therapeutics, Inc. has a twelve month low of $3.99 and a twelve month high of $10.99. The stock's fifty day simple moving average is $4.70 and its two-hundred day simple moving average is $5.56. The company has a market cap of $440.61 million, a P/E ratio of -4.67 and a beta of 1.46.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.01). As a group, equities research analysts predict that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in Lexeo Therapeutics in the 2nd quarter valued at $32,000. Allworth Financial LP raised its position in shares of Lexeo Therapeutics by 1,002.9% during the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company's stock worth $34,000 after acquiring an additional 3,079 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company's stock worth $35,000 after acquiring an additional 1,459 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Lexeo Therapeutics during the fourth quarter valued at $37,000. Finally, California State Teachers Retirement System lifted its position in Lexeo Therapeutics by 123.7% during the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company's stock valued at $39,000 after purchasing an additional 2,148 shares during the period. Institutional investors own 60.67% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Weiss Ratings raised Lexeo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 13th. JPMorgan Chase & Co. lowered their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, June 25th. Chardan Capital raised Lexeo Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Finally, Wall Street Zen downgraded shares of Lexeo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $18.75.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source